Why the study?
AF is often asymptomatic, leaving individuals unaware and untreated, while emerging screening technologies from medical-prescribed to consumer devices require summarizing current literature and clinical studies.
New digital health technologies offer promising, accessible methods for early detection of atrial fibrillation, but their routine clinical implementation requires further validation through large-scale randomized trials to prove cost-effectiveness and improved patient outcomes.
Digital AF screening tools merit consideration for asymptomatic detection; leaves open outcome benefits without RCTs.
Atrial fibrillation (AF) is a common and prevalent form of arrhythmia. It is associated with various morbidities with stroke being the major hazard. Since AF is often reported to be asymptomatic, many individuals remain unaware of their condition and may not receive the requisite treatment. Hence, screening for AF has gained substantial attention recently. Growing advancement in technology has paved way for numerous approaches for AF screening using medical-prescribed devices as well as consumer electronic devices. However, there still lies scope for large-scale randomized trials which would explore additional aspects associated with AF. This review very concisely summarizes AF, screening, present technology, current literature and clinical studies associated with it.
No takes yet. Share an insight, caveat, or question.
Adel Khalifa Hamad (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: